emerging markets strategy

Access to treatment-naïve patients spurs companies to look beyond the borders of their own countries.  Top markets such as the United States are home to hundreds of millions of patients, but the clinical trial market has been saturated with thousands of protocols...

Fresh news out of India this week is likely to add to pharmaceutical companies' concerns about pricing and sales in emerging markets.  Despite indications in February that compulsory licensing may be coming to an end, on March 18, BDR Pharmaceuticals applied for...

With continuing uncertainty in established markets such as the US and Europe, pharmaceutical companies are looking further abroad in pursuit of profits.  While many companies have been laying the groundwork to move into emerging markets for many years now, analysts...

Social media and mobile marketing have kick-started the pharma industry into a phase dubbed Pharma 3.0.  Gone are the days of Pharma 1.0 in which companies could rely on a handful of blockbuster drugs.  The diversified portfolio model of Pharma 2.0 is no longer...

In a recent study on HEOR teams, we found that accessing quality data for HEOR analysis is a challenge for companies worldwide. As shown in the accompanying Figure, on a scale of 1 to 10 (with 10 being the most difficult), US companies rated accessing quality data...

Saying that patient adherence is straightforward is like saying the only thing required to compete at the Olympics is a plane ticket. It’s simply not true. Fostering long-term patient adherence goes beyond the scope of simply getting patients to take their...

Mobile health (mHealth) may be the buzzword of today, but this one will not be just another flash in the pan. Mobile health offers the life sciences industry far-reaching capabilities to connect with various stakeholders - from patients and caregivers to physicians...

As pharmaceutical companies are feeling the economic downturn, many of them are shedding jobs. A FiercePharma article earlier this year pointed out that ten large pharmaceutical companies announced over 25,000 layoffs in 2011 – a figure that doesn’t include...

By Jeremy Spivey, Senior Research Analyst In an effort to expand Chinese citizens' access to certain high-volume pharmaceutical products, the Chinese government has committed to expanding a price-squeezing tendering system to the entire country. The...

Country-level medical affairs budgets currently average $1.9 million across Asia, Europe, North America and South America, according to our recent benchmarking study, with pharmaceutical and biotech companies boosting their investment in medical affairs affiliates...